<DOC>
	<DOCNO>NCT02081339</DOCNO>
	<brief_summary>Recent clinical introduction anti-vascular endothelial growth factor agent may change clinical course macular disease , include age-related macular degeneration ( AMD ) , polypoidal choroidal vasculopathy ( PCV ) , retinal angiomatous proliferation ( RAP ) , central serous chorioretinopathy ( CSC ) , myopic choroidal neovascularization ( CNV ) , retinal vein occlusion ( RVO ) , diabetic macular edema ( DME ) , forth . Patients macular disease register follow 5 year appropriate treatment patient . By analysis correlation initial examination final visual acuity , factor associate good visual prognosis elucidate .</brief_summary>
	<brief_title>Cohort Study Clinical Course Macular Diseases Japanese</brief_title>
	<detailed_description />
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patients visit Department Ophthalmology Kyoto University Hospital macular disease . Patients agree participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>